Biodesix $40 million follow-on offering
Davis Polk advised the underwriter in connection with the SEC-registered offering of 35,075,000 shares (including the exercise in full by the underwriter of its option to purchase up to 4,575,000 additional shares) of common stock of Biodesix, Inc. The offering resulted in approximately $40 million of proceeds to Biodesix, before deducting underwriting discounts and estimated offering expenses. Biodesix’s common stock is listed on the Nasdaq Global Market under the symbol “BDSX.”
Biodesix, headquartered in Boulder, Colorado, is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, Biodesix provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing and the discovery, development and commercialization of companion diagnostics.
The Davis Polk capital markets team included partner Richard D. Truesdell, Jr., counsel Alain Kuyumjian and associate Sean Choi. Counsel Alon Gurfinkel and associate Justin Corvino provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associates Brette L. Trost and Lauren Nathan. All members of the Davis Polk team are based in the New York office.